Wegovy/ Poviztra (Emcure co-marketed)Innovator semaglutide for obesity (chronic weight management) in India 2026
by Novo Nordisk · ₹5,660–16,400/month (post April 2026 price cut) · DCGI approved 2025–2026 (Wegovy), December 2025 (Poviztra via Emcure)
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Obesity (Chronic Weight Management) |
| Manufacturer | Novo Nordisk A/S |
| DCGI status | Approved 2025–2026 (Wegovy), December 2025 (Poviztra via Emcure) |
| Price (MRP) | ₹5,660–16,400/month (post April 2026 price cut) Effective April 1, 2026, Novo Nordisk reduced Wegovy prices ~48% in response to Indian generic launches. Emcure-distributed Poviztra runs ₹3,999–8,999/month after its own April 2026 price cut. |
| Format | Prefilled pen, five dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly) |
| Prescription | Schedule H — required |
How Wegovy compares
Wegovy is Novo Nordisk's original innovator brand of obesity-dose semaglutide (2.4 mg weekly) — the first DCGI-approved chronic weight-management semaglutide in India. Wegovy carries the SELECT cardiovascular outcomes label demonstrating 20% MACE reduction in adults with established CVD, a regulatory positioning Indian generics do not yet match. Sister brand Poviztra (Emcure-distributed under a Novo Nordisk partnership, December 2025 launch) extends Wegovy's reach into tier-2 and tier-3 Indian cities at lower price points — same molecule, broader distribution.
About Novo Nordisk
Novo Nordisk's STEP trial programme established the obesity-dose semaglutide evidence base, including STEP 1 (15.3% mean weight loss without diabetes), STEP 2 (T2D + obesity), and STEP 4 (continued treatment vs stopping). The SELECT trial extended this into cardiovascular outcomes, a label most Indian generics have not yet sought. The November 2025 Emcure partnership launched Poviztra as a tier-2/3 access brand using the same molecule.
Who is Wegovy for?
Wegovy is approved in India for chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5, or BMI ≥25 with weight-related comorbidities (T2D, PCOS, NAFLD, hypertension, dyslipidaemia, sleep apnea). Always confirmed by an endocrinologist or qualified physician.
Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →
Wegovy for specific conditions
Wegovy cost in India
MRP for Wegovy: ₹5,660–16,400/month (post April 2026 price cut). Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.
Full dose-by-dose pricing + hidden costs (consults, labs, needles): Wegovy price in India 2026 →
Compared to other GLP-1 brands in India
Wegovy is Novo Nordisk's innovator brand. Indian generic semaglutides (Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, Samakind, and others) contain the same active molecule at ₹1,290–3,500/month — substantially cheaper than Wegovy's ₹5,660–16,400/month (post April 2026 price cut). For tirzepatide (a different molecule with stronger weight outcomes), see Mounjaro.
Wegovy — frequently asked questions
Is Wegovy available in India? Is it DCGI-approved?+
What does Wegovy cost in India in 2026?+
Do I need a prescription to buy Wegovy?+
Who is Wegovy for?+
How does Wegovy compare to Indian generic semaglutides?+
Where can I buy Wegovy in India?+
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.